Oppenheimer reiterates a Buy on Questcor Pharmaceuticals (QCOR) following talks with U.S....

|By:, SA News Editor

Oppenheimer reiterates a Buy on Questcor Pharmaceuticals (QCOR) following talks with U.S. nephrologists who have experience with its Acthar MS drug. The firm believes the biggest headwind facing Acthar adoption is physician awareness, which it expects will be addressed by sales force expansion and new studies. Questcor was recently hit by a weak monthly sales report for Acthar.